Tag Archives: Swayampakula Ramakanth

Innate Pharma (IPHA) Receives a Buy from H.C. Wainwright

In a report issued on May 14, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Innate Pharma (IPHA – Research Report), with a price target of $13.00. The company’s shares closed last Thursday at $3.96, close to its

H.C. Wainwright Remains a Hold on Trillium Therapeutics (TRIL)

In a report issued on May 18, Swayampakula Ramakanth from H.C. Wainwright reiterated a Hold rating on Trillium Therapeutics (TRIL – Research Report). The company’s shares closed last Friday at $13.65. According to TipRanks.com, Ramakanth is a 1-star analyst with

H.C. Wainwright Believes Personalis (NASDAQ: PSNL) Still Has Room to Grow

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Personalis (PSNL – Research Report) on September 18 and set a price target of $30.00. The company’s shares closed last Tuesday at $23.85, close to its 52-week high of $24.87.

Ocugen (OCGN) Receives a Hold from H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on Ocugen (OCGN – Research Report) today. The company’s shares closed last Friday at $0.56, close to its 52-week low of $0.17. According to TipRanks.com, Ramakanth is a 3-star analyst with

Electrocore (ECOR) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Electrocore (ECOR – Research Report) today and set a price target of $3.00. The company’s shares closed last Thursday at $2.26. According to TipRanks.com, Ramakanth is a 1-star analyst with

Trillium Therapeutics (TRIL) Receives a Hold from H.C. Wainwright

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Hold rating on Trillium Therapeutics (TRIL – Research Report). The company’s shares closed last Wednesday at $8.34, close to its 52-week high of $9.66. According to TipRanks.com, Ramakanth